Glenmark Pharma reaches settlement agreement with Pfizer for Axitinib tablets

Mumbai: Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V., and PF Prism IMB B.V. for Axitinib tablets, 1 mg and 5 mg, the generic version of their Inlyta tablets, 1 mg and 5 mg.

Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib tablets, 1 mg and 5 mg on November 30, 2020.

According to IQVIATM sales data for the 12‐month period ending September 2022, the Inlyta tablets, 1 mg and 5 mg market achieved annual sales of approximately $644.5 million.